The global market for antibody drugs should grow from $126.7 billion in 2021 to $208.6 billion by 2026 with a compound annual growth rate (CAGR) of 10.5% for the period of 2021-2026.
The human antibody drugs market should grow from $58.4 billion in 2021 to $110.3 billion by 2026 with a compound annual growth rate (CAGR) of 13.6% for the period of 2021-2026.
The humanized antibody drugs market should grow from $50.1 billion in 2021 to $79.3 billion by 2026 with a compound annual growth rate (CAGR) of 9.6% for the period of 2021-2026.
Report Scope
This study offers a global view of the antibody drugs used in the pharmaceutical and biopharmaceutical markets. This report analyzes and assesses therapeutic applications of monoclonal antibodies (mAbs) in human medicine, including the combination of mAbs when they are attached to cytotoxic agents such as antibody drug conjugates.
The publisher analyzes and makes projections of each market and its applications, along with an analysis of the regulatory environment, new products, and technological advances. Also included in the report are relevant patent analyses and profiles of leading companies in the antibody drug industry, such as AbbVie Inc., Amgen Inc., Biogen Inc., Johnson & Johnson Inc., Merck KGaA, Novartis AG, F. Hoffmann-La Roche Ltd., and Merck & Co.
The report covers the major markets of the U.S., Europe, and the emerging markets in India, China, Japan, Korea, Taiwan, Africa, Australia, New Zealand, Canada, and others.
Monoclonal antibodies are protein-based therapies/drugs that are finding growing use in the treatment of chronic diseases. This report focuses on the global market for antibody drug products and provides an updated review on their applications in various disease sectors. The overall market for antibody drug products includes four main areas of applications: autoimmune diseases; solid tumors; lymphoma and leukemia; and other diseases such as asthma, osteoporosis, and cardiovascular diseases.
The report covers technology trends, including the human anti-mouse antibody (HAMA) problem caused by murine antibodies and how it was resolved by replacing murine antibodies with chimeric, human, and humanized antibodies.
This report excludes polyclonal antibodies, screening kits and diagnostic uses of mAbs. It also excludes the research applications of mAbs and therapeutic antibodies for veterinary use.
The Report Includes
- 30 data tables and 29 additional tables
- An overview of the global market for antibody drugs and related applications and technologies
- Analyses of global market trends, with data from 2019, 2020, estimates for 2021, and projections of compound annual growth rates (CAGRs) through 2026
- Identification of new opportunities, challenges, and technological changes within the industry and highlights of the market potential for antibody drugs by type, application, and region
- Detailed analysis of the current market trends, market forecast, and discussion of technological, and regulatory elements that are affecting the future marketplace
- Details of antibody functions, its comparison with antigen, and description of monoclonal antibodies, their history, advantages and disadvantages, types, manufacturing technologies and applications
- Coverage of new approvals, recalls, safety alerts and clinical trials of monoclonal antibodies and information on technical issues related to human anti-mouse antibody (HAMA), and factors affecting mAB drugs
- Information about major technologies for the formulation of antibody drugs and assessment of their relation to biotechnology, immunology, pharmaceuticals, and biodefense companies
- Market share analysis of the key companies of the industry and coverage of their proprietary technologies, strategic alliances, and other key market strategies
- Comprehensive company profiles of the leading players including F. Hoffmann-La Roche Ltd., Johnson & Johnson Inc., Novartis AG, Biogen Inc., Amgen Inc., and Merck & Co.
Table of Contents
Chapter 1 Introduction
- Study Goals and Objectives
- Reasons for Doing This Study
- Scope of Report
- Information Sources
- Methodology
- What's New in This Update?
- Geographic Breakdown
- Analyst's Credentials
- Custom Research
- Related Reports
Chapter 2 Summary and Highlights
Chapter 3 Market and Technology Background
- Antibodies and Antigens
- Antibody Functions
- Monoclonal Antibodies
- History of Monoclonal Antibodies
- Monoclonal Antibodies: Advantages and Disadvantages
- Types of Monoclonal Antibodies
- Manufacturing Technologies of Monoclonal Antibodies
- Applications of Monoclonal Antibodies
Chapter 4 Market Dynamics
- Technical Issues and HAMA Problem
- Human Anti-mouse Antibody (HAMA)
- Factors Affecting mAb Drugs
- Market Drivers
- Increasing Prevalence of Chronic Diseases
- Aging Population
- Advancements in Manufacturing Technologies
- New Product Launches
- Licensing and Collaboration Agreements
- Market Challenges
- Price Controls
- Regulatory Approval Pressures
- Entry of Biosimilars
- Impact of COVID-19 on Antibody Drugs Market
Chapter 5 Market Breakdown by Technology Type
- Market by Type
- Market Overview
- Market Revenue
- Market Share
- Market by Region
- Market Overview
- Market Revenue
- Market Share
- Humanized Monoclonal Antibodies
- Chimeric Monoclonal Antibodies
- Human Monoclonal Antibodies
- Murine Monoclonal Antibodies
- Market by Manufacturing Process
- Market Overview
- Market Revenue
- Market Share
- Market Analysis of Humanized Monoclonal Antibodies by Manufacturing Process
- Market Analysis of Chimeric Monoclonal Antibodies by Manufacturing Process
- Market Analysis of Human Monoclonal Antibodies by Manufacturing Process
- Market of Murine Monoclonal Antibodies by Manufacturing Process
Chapter 6 Market Breakdown by Application
- Market by Diseases
- Market Overview
- Market Revenue
- Market Share
- Autoimmune Disease
- Solid Tumors
- Lymphoma, Leukemia and Multiple Myeloma
- Others
Chapter 7 Regulatory Aspects
- New Approvals of Monoclonal Antibodies
- Recalls and Safety Alerts
Chapter 8 Patent Review/ New Developments
- New Developments
- Clinical Trial Phases
- Phase I Clinical Trials
- Phase II Clinical Trials
- Phase III Clinical Trials
- Phase IV Clinical Trials
Chapter 9 Competitive Landscape
- Mergers and Acquisitions
- Antibody Drugs
- Market Shares of Humanized Monoclonal Antibodies
- Market Shares of Human Monoclonal Antibodies
- Market Shares of Chimeric Monoclonal Antibodies
- Market Shares of Murine Monoclonal Antibodies
Chapter 10 Company Profiles
- Abbvie Inc.
- Amgen Inc.
- Alexion Pharmaceuticals
- AstraZeneca Pharmaceuticals
- Biogen
- Bristol-Myers Squibb Co
- Eli Lilly
- F. Hoffmann-La Roche Ag
- Fresenius Kabi
- Glaxosmithkline
- Genmab A/S
- Gilead Sciences Inc.
- Johnson & Johnson
- Merck & Co. Inc.
- Merck Kgaa
- Novartis Ag
- Pfizer Inc.
- Regeneron Pharmaceuticals
- Sanofi S.A.
- Seagen
- Takeda Pharmaceutical Co., Ltd.
- UCB Co.
List of Tables
Summary Table: Global Market for Antibody Drugs, by Antibody Type, Through 2026
Table 1: Evolution of Monoclonal Antibodies
Table 2: Advantages and Disadvantages of Monoclonal Antibodies
Table 3: Murine Monoclonal Antibodies
Table 4: Chimeric Monoclonal Antibodies
Table 5: Humanized Monoclonal Antibodies
Table 6: Human Monoclonal Antibodies
Table 7: Differences between Hybridoma and Recombinant Technologies
Table 8: Murine Monoclonal Antibodies and Their Applications
Table 9: Chimeric Monoclonal Antibodies and Their Applications
Table 10: Human Monoclonal Antibodies and Their Applications
Table 11: Humanized Monoclonal Antibodies and Their Applications
Table 12: Global Market for Antibody Drugs, by Antibody Type, Through 2026
Table 13: Global Market for Antibody Drugs, by Region, Through 2026
Table 14: Global Market for Humanized Monoclonal Antibodies, by Region, Through 2026
Table 15: Global Market for Chimeric Monoclonal Antibodies, by Region, Through 2026
Table 16: Global Market for Human Monoclonal Antibodies, by Region, Through 2026
Table 17: Global Market for Murine Monoclonal Antibodies, by Region, Through 2026
Table 18: Global Market for Monoclonal Antibodies, by Manufacturing Process, Through 2026
Table 19: Global Market for Humanized Monoclonal Antibodies, by Manufacturing Process, Through 2026
Table 20: Global Market for Chimeric Monoclonal Antibodies, by Manufacturing Process, Through 2026
Table 21: Global Market for Human Monoclonal Antibodies, by Manufacturing Process, Through 2026
Table 22: Global Market for Murine Monoclonal Antibodies, by Manufacturing Process, Through 2026
Table 23: Global Market for Antibody Drugs, by Disease, Through 2026
Table 24: Types of Autoimmune Diseases
Table 25: Global Market for Antibody Drugs in Autoimmune Disease, by Antibody Type, Through 2026
Table 26: Global Market for Antibody Drugs in Autoimmune Disease, by Region, Through 2026
Table 27: Types of Cancer by the Tissue of Origin
Table 28: Global Market for Antibody Drugs in Solid Tumor, by Antibody Type, Through 2026
Table 29: Global Market for Antibody Drugs in Solid Tumor, by Region, Through 2026
Table 30: Types of Leukemia
Table 31: Global Market for Antibody Drugs in Lymphoma, Leukemia and Multiple Myeloma, by Antibody Type, Through 2026
Table 32: Global Market for Antibody Drugs in Lymphoma, Leukemia and Multiple Myeloma, by Region, Through 2026
Table 33: Global Market for Antibody Drugs in Other Diseases, by Antibody Type, Through 2026
Table 34: Global Market for Antibody Drugs in Other Diseases, by Region, Through 2026
Table 35: Newly Approved Monoclonal Antibodies, 2019-August 2021
Table 36: Recalls and Safety Alerts, 2019-August 2021
Table 37: Monoclonal Antibodies in Phase I Clinical Trials
Table 38: Monoclonal Antibodies in Phase II Clinical Trials
Table 39: Monoclonal Antibodies in Phase III Clinical Trials
Table 40: Monoclonal Antibodies in Phase IV Clinical Trials
Table 41: M&A: Pharmaceutical Companies
Table 42: AbbVie Inc.: Business Segment
Table 43: AbbVie Inc.: Financial Performance, Through 2020
Table 44: Amgen: Financial Performance, Through 2020
Table 45: AstraZeneca: Financial Performance, 2018-2020
Table 46: Bristol-Myers Squibb: Financial Performance, 2018-2020
Table 47: Eli Lilly: Business Segment
Table 48: Eli Lilly: Financial Performance, 2018-2020
Table 49: F. Hoffmann-La Roche: Business Segment
Table 50: F. Hoffmann-La Roche: Financial Performance, 2018-2020
Table 51: GlaxoSmithKline: Product Segment
Table 52: Johnson & Johnson: Business Segment
Table 53: Johnson & Johnson: Financial Performance, 2018-2020
Table 54: Merck & Co. Inc.: Business Segment
Table 55: Merck & Co. Inc.: Financial Performance, 2018-2020
Table 56: Pfizer: Business Segment
Table 57: Sanofi: Business Segment
Table 58: Sanofi: Financial Performance, 2018-2020
List of Figures
Summary Figure: Global Market for Antibody Drugs, by Antibody Type, 2019-2026
Figure 1: Global Market for Antibody Drugs, by Antibody Type, 2019-2026
Figure 2: Global Market Shares of Antibody Drugs, by Antibody Type, 2020
Figure 3: Global Market for Antibody Drugs, by Region, 2019-2026
Figure 4: Global Market Shares of Antibody Drugs, by Region, 2020
Figure 5: Global Market for Humanized Monoclonal Antibodies, by Region, 2019-2026
Figure 6: Global Market for Chimeric Monoclonal Antibodies, by Region, 2019-2026
Figure 7: Global Market for Human Monoclonal Antibodies, by Region, 2019-2026
Figure 8: Global Market for Murine Monoclonal Antibodies, by Region, 2019-2026
Figure 9: Global Market for Monoclonal Antibodies, by Manufacturing Process, 2019-2026
Figure 10: Global Market Shares of Antibody Drugs, by Manufacturing Process, 2020
Figure 11: Global Market for Humanized Monoclonal Antibodies, by Manufacturing Process, 2019-2026
Figure 12: Global Market for Chimeric Monoclonal Antibodies, by Manufacturing Process, 2019-2026
Figure 13: Global Market for Human Monoclonal Antibodies, by Manufacturing Process, 2019-2026
Figure 14: Global Market for Murine Monoclonal Antibodies, by Manufacturing Process, 2019-2026
Figure 15: Global Market for Antibody Drugs, by Disease, 2019-2026
Figure 16: Global Market Shares of Antibody Drugs, by Disease, 2020
Figure 17: Global Market for Antibody Drugs in Autoimmune Disease, by Antibody Type, 2019-2026
Figure 18: Global Market for Antibody Drugs in Autoimmune Disease, by Region, 2019-2026
Figure 19: Global Market for Antibody Drugs in Solid Tumor, by Antibody Type, 2019-2026
Figure 20: Global Market for Antibody Drugs in Solid Tumor, by Region, 2019-2026
Figure 21: Global Market for Antibody Drugs in Lymphoma, Leukemia and Multiple Myeloma, by Antibody Type, 2020-2026
Figure 22: Global Market for Antibody Drugs in Lymphoma, Leukemia and Multiple Myeloma, by Region, 2020-2026
Figure 23: Global Market for Antibody Drugs in Other Diseases, by Antibody Type, 2020-2026
Figure 24: Global Market for Antibody Drugs in Other Diseases, by Region, 2020-2026
Figure 25: Global Market Shares of Humanized Monoclonal Antibodies, by Key Manufacturer/Supplier, 2020
Figure 26: Global Market Shares of Human Monoclonal Antibodies, by Key Manufacturer/Supplier, 2020
Figure 27: Global Market Shares of Chimeric Monoclonal Antibodies, by Key Manufacturer/Supplier, 2020
Figure 28: Global Market Shares of Murine Monoclonal Antibodies, by Key Manufacturer/Supplier, 2020
Figure 29: AbbVie Inc.: Net Revenue Share, by Business Segment, 2020
Figure 30: AbbVie Inc.: Net Revenue Share, by Region, 2020
Figure 31: Amgen: Sales Share, by Product, 2020
Figure 32: Amgen: Revenue Share, by Region, 2020
Figure 33: AstraZeneca: Sales Share, by Segment, 2020
Figure 34: AstraZeneca: Revenue Share, by Region, 2020
Figure 35: Bristol Myers Squibb: Sales Share, by Product, 2020
Figure 36: Bristol-Myers Squibb: Total Revenue Share, by Region, 2020
Figure 37: Eli Lilly: Total Sales Share, by Product Segment, 2020
Figure 38: Eli Lilly: Total Revenue Share, by Region, 2020
Figure 39: F. Hoffmann-La Roche: Total Sales Share, by Product Segment, 2020
Figure 40: F. Hoffmann-La Roche: Total Revenue Share, by Region, 2020
Figure 41: Johnson & Johnson: Total Sales Share, by Business Segment, 2020
Figure 42: Johnson & Johnson: Total Revenue Share, by Region, 2020
Figure 43: Merck & Co. Inc.: Revenue Share, by Business Segment, 2020
Figure 44: Merck & Co. Inc.: Revenue Share, by Region, 2020
Figure 45: Sanofi: Net Sales Share, by Business Segment, 2020
Figure 46: Sanofi: Net Sales Share, by Region, 2020
Samples
LOADING...
Executive Summary
Antibody drugs are created through the use of modern scientific techniques such as genetic engineering and recombinant deoxyribonucleic acid (DNA) technology. They are produced by living cells and organisms such as Escherichia coli (E. coli), yeast, mammalian cells, etc. These protein drugs have gained in significance due to the increase in the number of chronic diseases such as asthma, multiple sclerosis and arthritis, and fatal diseases such as cancer and cardiovascular diseases. The antibody drug industry has grown globally due to its pivotal role in the treatment of life-threatening diseases. This report analyzes and assesses the therapeutic applications of antibodies such as mAbs in human medicine, including the combination of mAbs when they are attached to cytotoxic agents, such as antibody drug conjugates.
Genetic engineering technology has made it possible to produce these protein molecules with modified features. Owing to its high specificity and low immunogenicity, protein therapeutics is widely used to treat various life-threatening diseases such as cancer, diabetes and multiple sclerosis. Increasing R&D, increasingly sedentary lifestyles, increasing incidence of various diseases and the growing population of baby-boomers are the driving forces for the monoclonal antibody market.
Leading manufacturers of mAbs include F. Hoffmann-La Roche Ltd., Johnson & Johnson Inc., Novartis AG, Biogen Inc., Amgen Inc., Merck & Co. and AbbVie Inc. Novel antibody drugs increasingly are being investigated and developed due to advances in technology. Approaches such as the development of antibody drug conjugates and bi-specific antibodies that attack the proteins present inside a cancerous cell are the present-day outlook of R&D of therapies. These therapies suppress the further progression of diseases such as arthritis, multiple sclerosis, hepatitis, Crohn’s disease, acquired immunodeficiency syndrome (AIDS), etc.
Human monoclonal antibodies (mAbs) are the largest segment in terms of revenue, followed by other mAb categories such as humanized, chimeric and murine. The use of mAbs in therapeutics such as oncology, autoimmune and inflammatory diseases should increase during the forecast period, although this market is likely to face competition from the entry of follow-on-biologics and biosimilars.The market increase also stems from the industry’s strong pipeline with many late-stage developmentmolecules.
The U.S. leads the antibody drugs market. Follow-on-biologics and price pressures are the major threats for the market. A rapid increase in medical technologies, improved diagnosis of disease and the expansion of healthcare in emerging markets are expected to positively impact the market. Also, the impact of COVID-19 has boosted growth in the antibody market as many monoclonal antibodies have granted emergency use authorization and approval for the treatment of COVID-19.
The market for antibody drugs is divided into four types of diseases: autoimmune diseases, solid tumors, lymphoma, leukemia and multiple myeloma, and other diseases such as asthma, osteoporosis, cardiovascular diseases and others. In 2020, the largest Shares of the antibody drug market belonged to oncology (solid and hematological malignancies).
Companies Mentioned
- Abbvie Inc.
- Alexion Pharmaceuticals
- Amgen Inc.
- AstraZeneca Pharmaceuticals
- Biogen
- Bristol-Myers Squibb Co
- Eli Lilly
- F. Hoffmann-La Roche Ag
- Fresenius Kabi
- Genmab A/S
- Gilead Sciences Inc.
- Glaxosmithkline
- Johnson & Johnson
- Merck & Co. Inc.
- Merck Kgaa
- Novartis Ag
- Pfizer Inc.
- Regeneron Pharmaceuticals
- Sanofi S.A.
- Seagen
- Takeda Pharmaceutical Co., Ltd.
- UCB Co.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 133 |
| Published | October 2021 |
| Forecast Period | 2021 - 2026 |
| Estimated Market Value ( USD | $ 126.7 Billion |
| Forecasted Market Value ( USD | $ 208.6 Billion |
| Compound Annual Growth Rate | 10.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 22 |
